PubMed Health⌕ Search

Biomedical subjects

F Viani

Publications and source records attributed to F Viani.

29 records · Page 2Linked to original sources
PubMed1990

Angelman's syndrome in the first year of life.

Angelman syndrome usually has been considered to be rare and sporadic. However, recent reports suggest a sibling recurrence risk of just under 25 per cent, so early diagnosis is very important. The authors report Angelman syndrome in a child of seven months. The early features of this syndrome (jerky movements, EEG characteristics, chromosomal abnormalities in half the cases) should make it possible to diagnose or suspect the syndrome in the first year of life.

Chromosome Banding↗
PubMed1987

Infantile febrile status epilepticus: risk factors and outcome.

The medical records of 68 children who had had infantile febrile status epilepticus (FSE) were examined. Follow-up periods ranged from three to 28 years (mean 8 years 10 months). Details were abstracted of relevant medical events prior to FSE, diagnosis of the febrile illness, age at onset and main characteristics of FSE, and outcome (subsequent febrile convulsions and/or epilepsy, neurological and psychiatric disorders). Neither medical events prior to FSE nor aetiology of fever were associated with subsequent febrile convulsions, epilepsy, or neurological or psychiatric abnormalities. There was a significant association between age at onset of FSE and both subsequent epilepsy and CNS disorders. 12 of the 13 children who had had transient or persistent post-ictal hemiparesis subsequently developed epilepsy. Of the 46 children who later developed epilepsy, 34 had partial seizures and 12 had generalized seizures. The latter were more common among children who had had FSE before the age of one year. Likewise, all those who developed severe myoclonic epilepsy in infancy had their first FSE before age one. These findings suggest that age at onset of FSE is the most important feature determining long-term outcome.

Child↗
PubMedDate not supplied

Classifications of epileptic syndromes: advantages and limitations for evaluation of childhood epileptic syndromes in clinical practice.

The advantages and limitations of the two most recent International League Against Epilepsy classifications of the epilepsies and epileptic syndromes have been assessed after examining the clinical records of 645 consecutive outpatients aged 1 month to 15 years followed at the Children's Epilepsy Center of the University of Milan, Italy, from 1977 through 1985. The percentage of cases that could be classified according to the 1970 and 1985 proposals for classification were 94.1 and 98.1%, respectively. According to the 1985 proposal, partial epilepsies (PE) and generalized epilepsies (GE) were almost equally represented (45.0 vs. 47.2%). Among PE, symptomatic epilepsies were the commonest variety. In the group of GE, idiopathic and/or symptomatic epilepsies were most common. Childhood absence epilepsy was the largest subgroup among idiopathic GE. Newly diagnosed patients, a less biased sample of the epileptic population represented 38.9% of the entire sample, and a proper classification was possible in 96% of cases. Idiopathic epilepsies were about twice as frequent and idiopathic and/or symptomatic GE less frequent in newly diagnosed patients when compared with the remainder. Marked differences in the frequency of the epilepsies were found in comparison with other reports in the literature which used the 1970 classification. This finding probably depends on different diagnostic assessment, selection bias, and different geographic and ethnic components, but it can also reflect the variable interpretation of the clinical and EEG features of a patient with epilepsy in the light of the artifactual categories of the classification.

Adolescent↗
PubMedDate not supplied

Comparative pharmacokinetic study of chewable and conventional carbamazepine in children.

Fifteen children (7 boys and 8 girls) with generalized tonic-clonic seizures (GTCS) and partial seizures with elementary or complex symptomatology, treated with carbamazepine (CBZ) alone (n = 7) or in combination with either phenobarbital (PB, n = 6) or clobazam (CLB, n = 2) given for at least 3 months at stable individualized doses and regimens, entered an open, within-patient, change-over study of consecutive periods, each lasting 2 weeks. During period 1, conventional CBZ was given; during period 2, a chewable CBZ formulation was substituted for conventional CBZ and given at the same total daily dosage with the same schedule as in period 1. Blood samples for measuring plasma concentration of both total CBZ and CBZ-10,11 epoxide (CBZ-E) were taken on the last day of each period. No significant difference between the two periods was noted in the mean +/- SD of Cmax, Css mean, and area under the curve (AUC) of total CBZ and CBZ-E. The two different CBZ formulations, administered at the same total daily dosage, can be considered bioequivalent.

Administration, Oral↗